School of Pharmaceutical Science and Technology, Health Science Platform, Tianjin University, Tianjin 300072, China.
J Mater Chem B. 2019 Feb 21;7(7):1056-1063. doi: 10.1039/c8tb03351j. Epub 2019 Feb 1.
Multifunctional nanocarriers have been widely applied due to their enhanced effect on tumor therapeutics. Nevertheless, owing to the natural immune clearance mechanisms in living bodies, nanocarriers tend to be eliminated during blood circulation, thereby impeding their effective arrival at the tumor sites. Herein, we constructed a synergetic targeted liposome nanocarrier system named SELS functionalized with both a tumor identification ligand (anti-ER (Estrogen Receptor) antibody) and an immune targeting ligand (Self-Peptide (SP)). The anti-ER antibody could recognize and bind ER-positive breast cancer tissues in a specific way. SP could activate the CD47-SIRPα immune response, which reduced phagocytosis of the nanoparticles by macrophages. Both the enhanced targeting ability and anti-phagocytosis behavior could improve the tumor uptake of the nanocarriers and prevent their immune clearance in living systems. Therefore, drug-loaded SELS enabled improved tumor imaging and therapeutic performance in living systems.
多功能纳米载体由于其在肿瘤治疗方面的增强效果而得到了广泛应用。然而，由于生物体中天然的免疫清除机制，纳米载体在血液循环中往往容易被清除，从而阻碍了它们有效到达肿瘤部位。在这里，我们构建了一种协同靶向脂质体纳米载体系统，命名为 SELS，它同时具有肿瘤识别配体（抗 ER（雌激素受体）抗体）和免疫靶向配体（自肽（SP））。抗 ER 抗体可以特异性地识别和结合 ER 阳性乳腺癌组织。SP 可以激活 CD47-SIRPα 免疫反应，从而减少巨噬细胞对纳米颗粒的吞噬作用。增强的靶向能力和抗吞噬作用都可以提高纳米载体在肿瘤中的摄取，并防止它们在生物体内被免疫清除。因此，载药的 SELS 可以提高药物在生物体内的肿瘤成像和治疗效果。
